Patents Assigned to Fundacio Institut de Recerca Biomedica (IRB Barcelona)
-
Patent number: 11591599Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: GrantFiled: April 3, 2018Date of Patent: February 28, 2023Assignees: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançaisInventors: Roger Gomis, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Patent number: 11535680Abstract: Targeting metastasis stem cells through a fatty acid receptor. The invention provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.Type: GrantFiled: September 29, 2016Date of Patent: December 27, 2022Assignees: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA, (IRB BARCELONA), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Salvador Aznar Benitah, Gloria Pascual Angulo, Andres Castellanos Martin, Merce Martin Peña
-
Publication number: 20220049316Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER-breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER-breast cancer metastasis.Type: ApplicationFiled: July 26, 2021Publication date: February 17, 2022Applicants: FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATSInventors: Roger GOMIS, Maria TARRAGONA, Anna ARNAL, Milica PAVLOVIC
-
Publication number: 20210380712Abstract: Targeting metastasis stem cells through a fatty acid receptor. The disclosure provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.Type: ApplicationFiled: September 15, 2020Publication date: December 9, 2021Applicants: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB Barcelona), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Salvador AZNAR BENITAH, Gloria PASCUAL ANGULO, Andres CASTELLANOS MARTIN, Merce MARTIN PEÑA
-
Patent number: 11072831Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: GrantFiled: July 6, 2018Date of Patent: July 27, 2021Assignees: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
-
Patent number: 10866241Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: GrantFiled: May 30, 2017Date of Patent: December 15, 2020Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)Inventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Publication number: 20190309299Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: April 3, 2018Publication date: October 10, 2019Applicants: Fundacio Institut de Recerca Biomedica (IRB Barcelona), Institucio Catalana de Recerca I Estudis AvancatsInventors: Roger GOMIS, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Publication number: 20190169693Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: ApplicationFiled: July 6, 2018Publication date: June 6, 2019Applicants: FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATSInventors: Roger GOMIS, Maria Tarragona, Anna Arnal, Milica Pavlovic
-
Publication number: 20190119757Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.Type: ApplicationFiled: May 21, 2018Publication date: April 25, 2019Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançatsInventors: Roger Gomis, Evarist Planet
-
Publication number: 20190084927Abstract: The present invention relates to 1-[1-(benzoyl )-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.Type: ApplicationFiled: September 26, 2018Publication date: March 21, 2019Applicants: UNIVERSITAT DE BARCELONA, FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA), IPROTEOS S.L.Inventors: Ernest Giralt Lledó, Teresa Tarragó Clua, Roger Prades Cosano, Soledad Royo Gracia
-
Patent number: 10125097Abstract: The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.Type: GrantFiled: November 11, 2013Date of Patent: November 13, 2018Assignees: UNIVERSITAT DE BARCELONA, FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), IPROTEOS S.L.Inventors: Ernest Giralt Lledó, Teresa Tarragó Clua, Roger Prades Cosano, Soledad Royo Gracia
-
Patent number: 10047398Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: GrantFiled: October 5, 2011Date of Patent: August 14, 2018Assignees: Fundacio Institut de Recerca Biomedica (IRB Barcelona), Institucio Catalana de Recerca I Estudis AvancatsInventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
-
Patent number: 10006091Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.Type: GrantFiled: June 6, 2013Date of Patent: June 26, 2018Assignees: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca I Estudis AvançatsInventors: Roger Gomis, Evarist Planet
-
Publication number: 20170370935Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: ApplicationFiled: May 30, 2017Publication date: December 28, 2017Applicants: Fundació Institut de Recerca Biomédica (IRB Barcelona), Institució Catalana de Recerca I Estudis AvancatsInventors: Roger GOMIS, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Patent number: 9744247Abstract: The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.Type: GrantFiled: June 28, 2013Date of Patent: August 29, 2017Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), FUNDACIÓ PARC CIENTÍFIC DE BARCELONA, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA), UNIVERSITAT DE BARCELONA, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA, UNIVERSITAT AUTÒNOMA DE BARCELONAInventors: Leonor Ventosa Rull, Jaume Veciana Miró, Ingrid Cabrera Puig, Elisa Elizondo Saez De Vicuña, Marta Melgarejo Diaz, Miriam Royo Expósito, Fernando Albericio Palomera, Daniel Pulido Martinez, Santiago Sala Vergés, Jose Luis Corchero Nieto, Simón Schwartz Navarro, Ibane Abasolo Olaortua, Antonio Pedro Villaverde Corrales
-
Publication number: 20170101683Abstract: The present invention relates to a method for the prognosis of bone metastasis in HER2+ breast cancer, which comprises determining if the MAF gene is amplified in a primary tumor sample. Likewise, the present invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the MAF gene expression level, amplification or translocation. The present invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The present invention also relates to a c-Maf inhibitor as therapeutic agent for use in the treatment of HER2+ breast cancer metastasis. The present invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the present invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.Type: ApplicationFiled: October 7, 2014Publication date: April 13, 2017Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançatsInventors: Roger GOMIS, Evarist PLANET, Milica Pavlovic, Anna ARNAL, Maria TARRAGONA
-
Patent number: 9475840Abstract: The peptides of formula (I) where: R1 is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from H, CH3C(?O)—, and maleimide; X is a biradical selected from —NH—(CH2)r—C(?O)—, —C(?O)—(CH2)r—C(?O)—, —S(CH2)r—, —S—(CH2)r—C(?O)—, —O—(CH2)r—, —S—CH—CH(NH2)—C(?O)—, —O—(CH2)r—C(?O)—, —(CH2)r—C(?O)—, —NH—O—CH2—C(?O)—NH—(CH2)r—CH(NH2)—C(?O)—, —(CH2)r—C(?O)—NH—(CH2)r—CH(NH2)—C(?O)—, and —NH—(CH2)r—CH(NHC(?O)CH2NH2)—C(?O)—; r is 1-5; P is a biradical of an amino acid sequence comprising the sequence D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1); Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is selected from —NH2, —OH, —OR2 and —NHR2; R2 is a radical selected from (C1-C6)-alkyl and (CH2)2—NH—C(?O)—CH2—O—NH2; k is 0-2; m is 0-1; with the proviso that when the biradical X is —C(?O)(CH2)r—C(?O)—, then R1 is H; when the N of the amino acid of the sequence P to which isType: GrantFiled: February 27, 2013Date of Patent: October 25, 2016Assignees: UNIVERSITAT DE BARCELONA, FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA)Inventors: Ernest Giralt Lledó, Meritxell Teixidó Turà, Roger Prades Cosano
-
Publication number: 20160139126Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: ApplicationFiled: March 15, 2013Publication date: May 19, 2016Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançatsInventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Publication number: 20160040247Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: ApplicationFiled: March 14, 2014Publication date: February 11, 2016Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Liuís Companys, 23Inventors: Roger GOMIS, Anna ARNAL, Maria TARRAGONA, Milica PAVLOVIC, Evarist PLANET
-
Publication number: 20160032400Abstract: The present invention relates to a method for the prognosis of bone metastasis in cancer which comprises using a probe to determine if a gene of interest is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise using a probe to determine the expression level of a gene of interest, or the amplification or translocation of a gene of interest. The invention also relates to a method for predicting early bone metastasis in a subject suffering cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of cancer metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering cancer and for classifying a subject from cancer into a cohort.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicants: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institucio Catalana de Recerca i Estudis AvancatsInventors: Roger GOMIS, Evarist PLANET, Milica PAVLOVIC, Anna ARNAL, Maria TARRAGONA